Gentian Diagnostics Asa · OSL:GENT
Gentian Diagnostics Asa — Q1 2021 Earnings Presentation
29 slides from Gentian Diagnostics Asa's earnings presentation, Apr 16, 2021
Slide 1: Q1 Presentation 2021
Q1 Presentation 2021 April 16th, 2021 Hilja Ibert, CEO Njaal Kind, CFO
Slide 2: Important notice
Important notice This presentation has been prepared by and is the sole responsibility of Gentian Diagnostics AS (the “Company” or “Gentian”). The presentation is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. The in
Slide 3: Agenda: Introduction and highlights
1. Introduction and highlights 2. Growth opportunities 3. Q1 financials 4. Outlook 3
Slide 4: Moving immunoassays to clinical chemistry analysers
Moving immunoassays to clinical chemistry analysers
Slide 5: We innovate diagnostic efficiency
We innovate diagnostic efficiency
Slide 6: Market
Market Clinical chemistry GLOBAL IVD MARKET W/O COVID-19 74.3 BUSD (2020) Focus on the immunoassay segment Detection and quantification of biomarkers which 16.9 support the diagnosis of inflammations, severe infections, kidney failures and congestive heart failures IVD other Gentian has acquir
Slide 7: Highlights for Q1 2021
Highlights for Q1 2021 Record sales revenue of MNOK 19.6 in 1Q21, a 33 % organic growth from the same period last year. Reported growth of 24 % on a currency neutral basis with 1Q20 including revenues from the subsidiary Pretect AS, which was divested in 2H20. fCAL® turbo sales growth of 60 % ve
Slide 8: Agenda: Growth opportunities
1. Introduction and highlights 2. Growth opportunities 3. Q1 financials 4. Outlook 8
Slide 9: Illustration of product categories and indicative market potential (USD)
Illustration of product categories and indicative market potential (USD) 9
Slide 10: Strategy for sustainable double-digit sales growth
Strategy for sustainable double-digit sales growth One innovative diagnostic product per year Competitive conversions of alternative technologies, mainly based on scientific evidence and a constantly enhanced distribution channel Increased market demand due to positive clinical impact 10
Slide 11: GCAL
In market development GCAL® Plasma and serum calprotectin Early biomarker for the detection and risk stratification of inflammation and severe infections
Slide 12: GCAL: Novel biomarker in market development
GCAL® : Novel biomarker in market development Promising biomarker for early detection, prognosis of disease severity and mortality of sepsis and other severe infections Scientific studies have demonstrated increased levels of calprotectin in COVID- 19 patients and indicating the prognostic value
Slide 13: Achievements in 1Q 2021
Achievements in 1Q 2021 Increased interest and implementation in routine testing Consistent and growing monthly sales underpins the commercial progress and market acceptance New customers implementing GCAL® in routine testing in Sweden, France and the Czech Republic GCAL ® distributor network
Slide 14: SARS-CoV-2 Total Antibody
Planned launch 4Q21 SARS-CoV-2 Total Antibody The first semi-quantitative turbidimetric antibody immunoassay for SARS-CoV-2 14
Slide 15: The new alternative for high volume SARS-CoV-2 serology testing
The new alternative for high volume SARS- CoV-2 serology testing Open system turbidimetric SARS-CoV-2 antibody testing for clinical chemistry analysers High throughput and efficient workflow with a cost-effective assay Addressing segments of immune status screening of the population, donor ide
Slide 16: NT-proBNP
Planned launch 2022 NT-proBNP First NT-proBNP on clinical chemistry analysers 16
Slide 17: Value proposition
Value proposition The Gentian NT-proBNP Immunoassay is the first turbidimetric in vitro diagnostic test for the quantitative measurement of NT-proBNP Gentian’s proprietary technology allows for comparable, consistent, biotin interference- free measurement of clinically relevant concentrations of
Slide 18: Expanded development scope with assumed positive effect on the adoption rate
Expanded development scope with assumed positive effect on the adoption rate The inconsistency of results from different instrument platforms and their respective assays has been described in the literature* The Gentian assay is instrument independent and with the choice of non-glycosylated targ
Slide 19: Additional achievements
Additional achievements The Gentian international patent application specifications were published by the WIPO in February 2021 Additional freedom-to-operate investigations have been carried out to monitor existing 3rd party rights using NT-proBNP in the cardiac field, without negative findings
Slide 20: Agenda: Q1 financials
1. Introduction and highlights 2. Growth opportunities 3. Q1 financials 4. Outlook 20
Slide 21: Financial highlights 1Q 2021
Financial highlights 1Q 2021 MNOK 1Q 2021 1Q 2020 Sales 19.6 16.2 Other Revenues 4.6 2.9 Total Revenues 24.2 19.1 COGS 10.5 9.9 R&D Costs 7.7 5.6 SG&A 9.5 8.5 Capitalization -1.5 -0.1 OPEX 26.1 24.0 EBITDA -1.9 -4.9 EBIT -3.9 -6.5
Slide 22: Sales and revenues
Sales and revenues Sales revenues - geographic split Consolidated Revenues (MNOK) MNOK 1Q21 1Q20 US 0.4 0.7 26,0 Europe 14.0 11.2 24,0 22,0 Asia 5.2 4.3 20,0 18,0 19.6 16.2 Total 16,0 14,0 12,0 Sales revenues - product split 10,0 8,0 MNOK 1Q21 1Q20 6,0 4,0 Cystatin C 7.4 6.6 2,0 0,0 fCAL® turbo 8.5
Slide 23: Sales Cystatin C
Sales Cystatin C Kidney function test, diagnosis and monitoring NOK Cystatin C 9 000 000 8 000 000 Increase of 12 % compared to 1Q20 7 000 000 6 000 000 Sales in Asia continue to grow and was up 23 % 5 000 000 compared to 1Q20 4 000 000 3 000 000 Sales in Europe and the US was somewhat lower t
Slide 24: Sales fCAL turbo
Sales fCAL® turbo Test for inflammatory bowel disease (IBD), diagnosis and monitoring NOK fCAL® turbo 9 000 000 Record sales of MNOK 8.5 a 60 % increase in 8 000 000 growth compared to 1Q20 7 000 000 6 000 000 The growth was driven by increased demand for both kit and bulk segments 5 000 000 4 0
Slide 25: OPEX
OPEX OPEX before capitalization OPEX 1Q21 20 000 000 18 000 000 16 000 000 14 000 000 12 000 000 R&D 45 % 10 000 000 OPEX 8 000 000 55 % 6 000 000 4 000 000 2 000 000 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2019 2020 2021 Total OPEX ex COGS before capitalization (1Q21): MNOK17.2
Slide 26: Cash flow and cash position
Cash flow and cash position MNOK 1Q21 2020 1Q20 Operating activities -9.4 -9.7 -9.7 Investing activities - 2.2 - 4.6 -0.4 Financing activities 0.1 0.7 -0.1 Changes in cash and cash equivalent -11.8 - 13.6 -10.2 Cash and cash equivalent at the beginning of period 158.0 171.6 171.6 Cash and cash equiv
Slide 27: Agenda: Outlook
1. Introduction and highlights 2. Q1 Financials 3. Growth opportunities 4. Outlook 29
Slide 28: Outlook
Outlook For cystatin C, increasing demand is foreseen in Asia as well as in the US as a result of targeted commercial and marketing initiatives from both Gentian and its partners. Continued customer and regional expansion of fCAL® turbo is expected in 2021, fuelling growth. In addition to contin
Slide 29: Get in touch with us
Get in touch with us www.gentian.com – info@gentian.com HQ GENTIAN AS Bjørnåsveien 5, 1596 Moss, Norway GENTIAN DIAGNOSTICS AB Kungsgatan 8, 111 43 Stockholm, Sweden GENTIAN USA INC. 215 N Eola Dr, Orlando, Florida US BEIJING REP. OFFICE Chaoyangmen Outer St Jia No.10 Chaoyang District, Beijing, Chi